Inside Abbelight's EIC Accelerator Project on Nanoscale Imaging

Light microscopes cannot separate two points closer than about 250 nanometres. Single-molecule localization microscopy, the technique honoured by the 2014 Nobel Prize in Chemistry, gets around that limit by switching fluorescent molecules on a few at a time and pinpointing each one, reaching 5 to 10 nanometres. The catch is speed: building one image takes thousands of frames over a tiny patch of sample. Abbelight, a spin-out of the Institut des Sciences Moléculaires d'Orsay, sells add-on modules that turn a standard inverted microscope into such a nanoscope. In the October 2019 cut-off of the EIC Accelerator pilot, the European Commission selected its project HT-SAFe for blended finance, a grant plus EIC equity. The list names Abbelight alone, with no partner companies, and places it in Paris, where its registered office stood until January 2020.

The grant was €1,203,160 towards a €1,718,800 project that ran from 1 May 2020 to 31 August 2022, according to CORDIS. The aim was to make nanoscopy a thousand times more productive: a fully automated, high-throughput platform with automated sample preparation and a cloud service for storing and analysing the data with deep learning, sold together with Olympus, which the proposal called its "new distributor partner".

Abbelight in 2026

Abbelight is active and growing. In January 2026 it announced a Series B led by AVANT BIO, a growth equity firm focused on tools for drug development, to expand sales and adapt its systems to single-cell phenotyping and to validating how drugs act in cells, according to Pulse 2.0 and StartupRise. Neither report gives the amount. Both quote chief executive Jean-Baptiste Marie on supporting the company's "100+ installed base", and Pulse 2.0 puts the team at about 60 people. The register shows two capital increases around the round, in December 2025 and June 2026, which took nominal share capital from €60,065 to €95,510, according to societe.com and North Data. The 2025 accounts were filed in September 2026, as the official company directory records, and no insolvency proceedings appear.

The Technology: Making Nanoscopy Fast Enough for Screening

Abbelight's SAFe platform is modular: excitation and detection units bolt onto existing inverted microscopes from other makers, and the Neo software reconstructs the images and analyses clusters, colocalisation and particle tracks, according to the company's product pages. The company also sells reagent kits and an automated sample preparation system, Smart Flow. Its pitch against established super-resolution microscopes is that labs can upgrade an instrument they already own, and that it covers the whole chain from sample to analysis.

HT-SAFe went after throughput. A standard single-molecule microscope lights its sample with a Gaussian laser spot, so only a small central area is evenly illuminated. Abbelight's answer was ASTER, a fast scanning illumination that spreads the light evenly over a much wider field. The method was published in Nature Communications in May 2021 by Adrien Mau, Karoline Friedl, Christophe Leterrier, Nicolas Bourg and Sandrine Lévêque-Fort, with a preprint from May 2020. The two sources size the gain differently: the paper speaks of fields of view 25 times larger than typical, while the company's CORDIS report says one shot covers about 64 times the market standard. The second half of the gain came from "spectral demixing", which records up to three fluorescent labels at once instead of one.

What HT-SAFe Promised, and What CORDIS Shows

The published periodic report is short and reads like a mid-project update. It is labelled as the report for the second period, from May 2021 to August 2022, but it describes work done in 2020 and calls the Nature Communications paper "in press". It says throughput rose by a factor of about 200, that ASTER is built into all Abbelight imaging products, and that a new product, the SAFe redSTORM, was developed for multicolour imaging. It says nothing about the cloud service, the neural network analysis or an automated high-content screening system, which were the core of the proposal.

1. Higher imaging throughputDeliveredAbout 200-fold, per the CORDIS report; ASTER peer-reviewed in Nature Communications.
2. Multicolour imaging productDeliveredSAFe redSTORM with spectral demixing, per CORDIS.
3. Automated sample preparationPartlySmart Flow is sold as an "automated workflow system"; no high-throughput, plate-based version is public.
4. Cloud SaaS with deep learning analysisNot achievedNot mentioned in the CORDIS report or on the company's product pages.
5. Over 70 customers and €30M turnover in 2023Not achievedNo turnover published; 2023 net loss of €2.30M. 100+ systems installed by 2026.

The fair reading is that the grant paid for a real optical advance that went straight into the product line, while the platform the proposal described, an automated, connected nanoscope for pharmaceutical screening, did not appear as a product. Some of that ambition moved into later EU projects. Abbelight receives €550,000 in RT-SuperES, an EIC Pathfinder project running from July 2023 to June 2027 that aims to build a "commercial real-time SR-highcontent imaging system" steered by machine learning, and €796,250 in nanoSCAN, an EIC Transition project from October 2023 to September 2026 built around a multi-scale imaging platform named SAFe-nSCAN for spatial biology. Both are listed on North Data with the same amounts. Before HT-SAFe, Abbelight had a €50,000 SME Instrument Phase 1 grant for NanoMAPs in 2017, whose plan already promised cloud software and automated imaging and forecast "about € 22 million" in turnover by 2022.

The Money

The EIC equity part of the award did happen. Abbelight is listed in the EIC Fund portfolio as a maker of "super-resolution microscopes for medical research", and it appears on the first page of the official list of invested companies. Neither page gives an amount or a date. Tracxn dates an EIC Fund entry to April 2022, and the register shows capital increases in February and August 2021 and April 2023, but which of these carried the EIC money is not public.

Revenue is harder to see. Abbelight files its annual accounts with a confidentiality declaration, as every BODACC filing notice from 2018 to 2026 states. The register's financial ratio data give net losses of €598,032 for 2018, €1,075,849 for 2022 and €2,296,458 for 2023, the last figure also shown by the company directory. The same data put equity at minus 7.5% of total assets at the end of 2022 and 46.8% a year later, after the April 2023 capital increase. The last revenue figure Abbelight published itself is in the HT-SAFe proposal: €1.3 million between July 2017 and June 2019.

Why Europe Should Care

Research instruments are a quiet part of the life sciences supply chain. The Commission's Strategy for European Life Sciences, adopted on 2 July 2025, aims to make Europe the most attractive place for life sciences by 2030, backed by more than €10 billion a year from the EU budget, according to the Commission and FASI. A French maker of nanoscale imaging tools, built on public research and now aiming at drug discovery, fits that agenda. The public side of the partnership has deepened too: in February 2024 Abbelight, the CNRS and Université Paris-Saclay opened a joint laboratory, Nanolife, to develop a new single-molecule instrument "covering the entire value chain", according to Université Paris-Saclay.

The Verdict

Abbelight has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.